We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ergomed Plc | LSE:ERGO | London | Ordinary Share | GB00BN7ZCY67 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1,346.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
26/5/2020 08:39 | Bought back in here chart looks good for a rise | nw99 | |
20/5/2020 12:46 | Ergomed@ErgomedPLC Clinical Trials Day is the perfect opportunity to pause a moment and pay tribute to everyone who improves #Healthcare through #clinicalresearch. Ergomed would like to acknowledge our dedicated employees and everyone who is dedicated to making the world a safer place. #CTD2020 | piedro | |
18/5/2020 07:48 | Yep, have no idea of exactly how this will work but seems to make perfect sense to use AI in a business like pharmacovigilance where you have huge volumes of data and information coming in and out and good to see Ergomed embracing the tech. | bermudashorts | |
18/5/2020 07:08 | Nice rns- if only they provided an every day language translation. But they obviously like it! | ayl30 | |
30/4/2020 11:01 | Bought back into this earlier | montynj | |
29/4/2020 16:07 | According to information on the Hargreaves Lansdown site , Ergomed is the tenth-biggest holding of the LF Miton UK Value Opportunities fund ( Class B Accumulation ) , constituting 2% of the fund which has a total value of £ 326 million . However , it is feasible that the information from HL is not fully up-to-date . Good luck all . | mrnumpty | |
06/4/2020 09:03 | Also involved in a Covid-19 trial in the US (world's biggest pharma market). From RNS from 30.03.2020: '...today announces that it will provide drug safety services through its specialist pharmacovigilance provider, PrimeVigilance, for an ongoing US clinical trial to assess the effect of a rheumatoid arthritis treatment on patients with severe COVID-19 infection.' | mfhmfh | |
06/4/2020 08:00 | Second Covid19 deal. Excellent. | blueflame | |
05/4/2020 08:20 | Multiple posts could be malware be careful. | sidam | |
04/4/2020 11:27 | Interesting follow up in this wknds SCSW, although those that get the heads up bought yesterday! | investographer | |
04/4/2020 00:52 | Really strong end to the week after some very positive news. Hopefully comment in SCSW over the weekend. | blueflame | |
03/4/2020 16:17 | What happened to Haemostatix? | greg the grinch | |
02/4/2020 10:14 | likely more work or Erogmed to come: 'Lee Morley, Chief Executive Officer, EUSA Pharma, said: "...We look forward to engaging in further studies to research the potential of siltuximab for patients suffering severely with respiratory complications from COVID-19..." | mfhmfh | |
02/4/2020 07:57 | Could outperform | nw99 | |
02/4/2020 07:17 | Further encouraging news in today's rns | ayl30 | |
30/3/2020 08:52 | More good news today, this could be a great little share to own in these difficult times | ayl30 | |
28/3/2020 10:01 | Results Presentation | piedro | |
26/3/2020 12:28 | Yes very good interview. They seem really confident that business will hold up really well over the coming year with the added chance of further Covid 19 work. Very reassuring. | blueflame | |
26/3/2020 10:59 | mfhmfh, Thank you for the link The lady seems very positive and there could be more to trials to come. | piedro | |
26/3/2020 10:12 | Ergomed's work is mandatory/based on compliance, etc. business seems to be continuing as normal in these difficult times: | mfhmfh |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions